Navigation Links
Medarex Announces Completion of Sale of Shares in Genmab A/S
Date:2/1/2008

PRINCETON, N.J., Feb. 1 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that it has completed the sale of approximately 2.5 million shares of Genmab A/S which stock is traded on the Copenhagen Stock Exchange. The trade is expected to settle on February 1, 2008. Medarex expects to receive approximately $151.8 million (USD) in net proceeds from the sale. The sale of Genmab shares reduces Medarex's ownership in Genmab to approximately 5.1 percent.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 30 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase III clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its Web site at http://www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
2. Medarex Announces Election of Marc Rubin as New Board Member
3. Medarex to Present at the UBS Global Life Sciences Conference
4. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
5. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
6. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
7. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
8. Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application
9. Rigel Announces Pricing of Public Offering of Common Stock
10. Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Third Quarter Results on Friday, February 8, 2008
11. Healthcare Technologies Ltd. Announces the Change of its Name to "NexGen Biofuels Ltd"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... IL (PRWEB) , ... December 01, 2016 , ... ... to congratulate long-term client Nanowear on their recent FDA Class II 510(k) clearance ... cleared a significant hurdle in commercializing remote cardiac monitoring devices that rely on ...
(Date:12/2/2016)... , December 2, 2016 The immunohistochemistry ... growing at a CAGR of 7.3% during the forecast period of ... and diagnostic laboratories segment accounted for the largest share of immunohistochemistry ... ... on global immunohistochemistry (IHC) market spread across 225 pages, profiling 10 ...
(Date:11/30/2016)... 2016 The global Pyrogen Testing ... a dominant share in the overall market. The leading ... and Merck KGaA, held a lion,s share of 51% ... observes that these companies are expected to retain their ... are do not require rabbit pyrogen testing along with ...
(Date:11/30/2016)... /PRNewswire/ -  Equicare Health Inc ., the leading supplier ... one of the top 100 companies in the 2016 ... distinguishes the top digital health companies across the globe. ... this year continually upgrading our product with the ongoing ... team," says Len Grenier , CEO of Equicare ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016   ... management and verification solutions, has partnered with ... software solutions for Visitor Management, Self-Service Kiosks ... provides products that add functional enhancements to ... provides corporations and venues with an automated ...
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
Breaking Biology News(10 mins):